HARMONY Alliance participates in 18th ELN symposium

HARMONY Experts will present and participate in the 18th Symposium of the European LeukemiaNet /21st Symposium of the Kompetenznetz Leukämien, organized in-person in Mannheim, Germany at the Congress Center Rosengarten, on March 15th, 2022.

ELN is a publicly funded research network of excellence that aims to improve the treatment of leukemia through coordinated research efforts across Europe. ELN is a HARMONY and HARMONY PLUS Partner.

Topics to be addressed and discussed at the ELN-HARMONY session

Updates and next steps about HARMONY and HARMONY PLUS
HARMONY Research leads the way in AML
HARMONY Research Project about Clonal dynamics in CML
HARMONY Delphi Hackathon in CML, HL, MPN and WM

HARMONY Expert speakers

Jesús María Hernández Rivas, IBSAL, HARMONY Coordinator
Guillermo Sanz, Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana, HARMONY Co-Chair
Lars Bullinger, Charite Berlin, HARMONY Lead Core Outcome Sets
Rudiger Hehlmann, ELN Foundation, HARMONY Lead Data Platform
Thomas Ernst, ELN-Universitätsklinikum Jena, HARMONY CML Research
Jesse Tettero, Amsterdam UMC, HARMONY AML MRD Research
Katharina Lang, Charite Berlin, HARMONY Co-Lead Core Outcome Sets
Renate Schulze-Rath, Bayer, HARMONY Co-Lead Core Outcome Sets

More information and valuable downloads about HARMONY Alliance Leukemia research

Learn more about our projects aiming to improve the treatment of leukemia and check out the HARMONY Alliance Research Projects >
Learn more about the HARMONY Alliance Big Data Platform, a central database and state-of-the-art Big Data analytic services >
Learn more about the HARMONY Alliance Delphi Survey studies >

HARMONY Partner Rüdiger Hehlmann, Professor of Medicine and founder/chair of the European LeukemiaNet: "HARMONY is focusing on a broad range of blood cancers, including acute and chronic leukemias, and the ELN has has joined HARMONY from the start. By assembling anonymized data sets of thousands of patients into the unique HARMONY Big Data Platform, we can characterize the molecular landscape of these diseases, understand their pathophysiology, and identify novel drug targets. In addition, it will allow us to reliably predict disease course and drug response for subgroups of patients. HARMONY’s results should ultimately provide tools for healthcare professionals to rapidly select the most promising treatment for an individual patient with leukemia."

#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

The HARMONY Alliance (HARMONY and HARMONY PLUS) is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

HARMONY: 53 Partners and 48 Associated Members, including 9 European Patient Organizations from 18 countries. Budget: 40 million | January 2017- June 2023

HARMONY PLUS: 39 Partners from 10 countries. Budget 12 million. Period: October 2020 – September 2023

More information? contact: Ellen de Waal, HARMONY Communications Lead: e.dewaal@ehaweb.org
www.harmony-alliance.eu | www.bigdataforbloodcancer.eu | @HARMONYNetEU

Receive the latest news. Click here to subscribe!